Case Western Reserve University School of Medicine, Cleveland, OH; University Hospitals Cleveland Medical Center, Cleveland, OH.
Wake Forest School of Medicine, Winston-Salem, NC.
Urology. 2020 Dec;146:140-144. doi: 10.1016/j.urology.2020.09.004. Epub 2020 Sep 15.
We hypothesize that men with diabetes mellitus whose inflatable penile prosthesis (IPP) implantation is delayed for unacceptably high hemoglobin A1c (HbA1c) will have durable improvements in their glycemic control after achieving acceptable HbA1c levels for surgery.
Per institutional protocol, an A1c <9% must be documented prior to IPP placement. After IRB approval, a single surgeon IPP database was retrospectively queried for data specific to diabetes mellitus management. Men without HbA1c values at ≥1-year follow-up were excluded. Univariate and multivariate statistical analyses were performed to assess associations with sustained HbA1c control.
From January 2011 to March 2019, 138 diabetics undergoing IPP were identified. Thirty-seven were excluding for insufficient follow-up. Nineteen of the 101 analyzed men (18.8%) were delayed a median 4 months (range 2-17) for elevated HbA1c values (median 10.1, range 9.1-12.3). Following improvements, median preoperative HbA1c remained higher (8.2% vs 7.0%) in delayed men (P < .001). Among delayed recipients, 11 (58%) improved without medication changes while insulin was newly initiated (5) or dosage was increased (5) in 42%. At 32 months follow-up, a HbA1c <9% was similarly maintained in delayed and nondelayed men (74% vs 87%, P = .17). Delayed men more commonly required insulin therapy at follow-up (89.5% vs 54.9%, P = .008), but had a similar median change in BMI (+0.1 vs +0.1, P = .65). Device infection occurred in 1 nondelayed patient (0.7%).
Men who improve HbA1c for IPP surgery are likely to demonstrate persistent improvement. IPP implantation appears to be safe in diabetic men with HbA1c <9%.
我们假设糖尿病男性,如果其可充气阴茎假体(IPP)植入术因糖化血红蛋白(HbA1c)过高而被延迟,在达到手术可接受的 HbA1c 水平后,其血糖控制将得到持久改善。
根据机构方案,在进行 IPP 放置之前,必须记录 A1c<9%。在获得 IRB 批准后,对一名外科医生的 IPP 数据库进行了回顾性查询,以获取特定于糖尿病管理的数据。排除了在至少 1 年随访时没有 HbA1c 值的男性。进行了单变量和多变量统计分析,以评估与持续 HbA1c 控制相关的因素。
2011 年 1 月至 2019 年 3 月,共确定了 138 例糖尿病患者接受了 IPP。37 例因随访时间不足而被排除。在分析的 101 名男性中,有 19 名(18.8%)因 HbA1c 值升高(中位数为 10.1,范围为 9.1-12.3)而延迟了中位数为 4 个月(范围为 2-17)。延迟组男性的中位术前 HbA1c 仍然较高(8.2% vs 7.0%)(P<.001)。在延迟组中,11 名男性(58%)在不改变药物治疗的情况下得到改善,而在 42%的患者中,新开始使用胰岛素(5 例)或增加胰岛素剂量(5 例)。在 32 个月的随访中,延迟组和非延迟组男性的 HbA1c<9%同样维持(74% vs 87%,P=0.17)。在随访中,延迟组男性更常需要胰岛素治疗(89.5% vs 54.9%,P=0.008),但 BMI 的中位数变化相似(+0.1 与 +0.1,P=0.65)。在 1 名非延迟患者中发生了设备感染(0.7%)。
为 IPP 手术改善 HbA1c 的男性,其血糖控制可能会持续改善。在 HbA1c<9%的糖尿病男性中,IPP 植入术似乎是安全的。